We are live on ! Find out more
ADMA icon

ADMA Biologics
ADMA

19 hedge funds and large institutions have $45M invested in ADMA Biologics in 2017 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

6% more funds holding

Funds holding: 18 → 19 (+1)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1.12% less ownership

Funds ownership: 72.71% → 71.59% (-1.1%)

6% less capital invested

Capital invested by funds: $48M → $45M (-$2.95M)

Holders
19
Holders Change
+1
Holders Change %
+5.56%
% of All Funds
0.47%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
3
Increased
5
Reduced
4
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$94.1K
2
Northern Trust
Northern Trust
Illinois
+$52.1K
3
SIM
Spark Investment Management
New York
+$26.7K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$22.9K
5
PCM
Prelude Capital Management
New York
+$13.3K

Top Sellers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
-$417K
2
WMSA
Weiss Multi-Strategy Advisers
New York
-$296K
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$115K
4
TRCT
Tower Research Capital (TRC)
New York
-$94

ADMA Hedge Fund Activity: Q1 2017 in Review

19 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q1 2017, worth a combined $45M — down 6.2% from $48M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new ADMA positions and 0 closed out — a net gain of 3 holders — while 5 added to existing stakes and 4 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $94.1K. The largest seller was Broadfin Capital, cutting an estimated $417K.

  • 19 institutional investors held ADMA Biologics (ADMA) as of Q1 2017, up from 18 in Q4 2016.
  • Funds reported $45M of ADMA Biologics stock for Q1 2017, down 6.2% quarter-over-quarter.
  • 3 funds opened new ADMA Biologics positions in Q1 2017 and 0 closed out, a net change of +3 holders.
  • The largest ADMA Biologics buyer in Q1 2017 was BlackRock, an estimated $94.1K added.
  • The largest ADMA Biologics seller in Q1 2017 was Broadfin Capital, an estimated $417K sold.

Based on aggregated 13F filings for Q1 2017.